DNA/GENE MICROARRAY MARKET ANALYSIS

DNA/Gene Microarray Market, By Type (Oligonucleotide DNA Microarrays, Complementary DNA Microarrays),By Application (Genomics, Proteomics, Agricultural Biology, Environment, Drug Research and Development, Cancer/oncology, Others (SNP Analysis, etc.)),By End User (Biopharmaceutical and Pharmaceutical Companies, Diagnostic Laboratories, Research Laboratories, Others (Academic Institutes, etc.)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global DNA/Gene Microarray Market: Key Developments

On January 15, 2023, National Center for Biotechnology Information, announced the development of a microarray system to detect UDP-glucuronosyltransferase gene polymorphisms for use in clinical laboratories in patients eligible for irinotecan hydrochloride treatment. It allows the construction of a measurement system for high-density and DNA fixation clinical applications.
In November 2022, Sengenics, a precision medicine company, announced the commercial launch of dual-color IgG/IgA assay services. The new dual-color assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.
In May 2022, Qatar Genome Program, a research institute, and Thermo Fisher Scientific, a provider of diagnostic solutions, announced a partnership to accelerate genomic research and clinical applications of predictive genomics in Qatar. This partnership expanded the advantages of precision medicine across the Middle East. Moreover, it comprises custom genotyping arrays designed to boost clinical applications of predictive genomics.
In February 2021, 23andMe, a biotechnology company, announced it they had merged with VG Acquisition Corp., a bank investment company. This merger would provide capital funds for their genetic consumer health business and genetic research activities.